This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Why Covidien Stock Is Still Undervalued Despite the Medtronic Deal

Stocks in this article: COVMDTABTJNJMNKSYK

NEW YORK (TheStreet) – You don't need me to tell you there's value in Covidien (COV). Just ask the management at Medtronic (MDT), which recently agreed to buy Covidien for $42.9 billion.

At a 29% premium to Covidien's prior closing price, the company's investors became wealthier overnight. The stock closed Wednesday at $89.29. Shares are up 32% on the year to date, outperforming the health care sector's 13% gain. But it's not time to get complacent.

Instead of thanking Medtronic, try to understand the nature of its proposed offer. You will find that Covidien is still undervalued by 8%. From my calculations, the stock is worth at least $97 per share. The company reports fiscal third-quarter results Friday.

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

Why Facebook Is Even Scarier Than You Realize

Hedge Funds Hate These 5 Stocks -- Should You?

Prior to the announced deal, Covidien shares traded at around $72, as of the June 13 closing price. Medtronic made its move on June 15. On June 16, Covidien shares soared to an intraday high to $92.68 and closed at $86.75.

Over the past month, the stock has traded in a tight range between $88 and $91. This is because investors have not factored the implied value of Covidien based on Medtronic's offer.

First, the deal, which will be financed with $35.19 billion in cash and stock, values Covidien at $93.22 per share. This means Covidien is already discounted 4.4% based on Wednesday's closing price. That's money left on the table.

Second, the stock swap calls for Covidien investors to receive 0.956 shares of Medtronic for each Covidien shares they own. So, with Medtronic shares closing Wednesday at $63.37, this means an additional 4% discount has been added to the overall purchase price of Covidien.

The way I see it, there is a combined 8.4% premium that belongs to Covidien shares. Assuming that the deal closes by early 2015, investors who are willing to capitalize on the market's mistake will begin 2015 with potentially 10% to 12% annualized gains based on $4.45 earnings estimates.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs